Nicholas Company Inc. raised its stake in Icon Plc (NASDAQ:ICLR) by 7.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,495 shares of the medical research company’s stock after acquiring an additional 4,925 shares during the period. Nicholas Company Inc. owned approximately 0.13% of Icon Plc worth $7,089,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently made changes to their positions in ICLR. Shine Investment Advisory Services Inc. acquired a new position in Icon Plc in the 2nd quarter valued at $103,000. Parallel Advisors LLC raised its holdings in Icon Plc by 20.7% in the 2nd quarter. Parallel Advisors LLC now owns 1,265 shares of the medical research company’s stock valued at $133,000 after acquiring an additional 217 shares in the last quarter. US Bancorp DE raised its holdings in Icon Plc by 15.0% in the 1st quarter. US Bancorp DE now owns 1,929 shares of the medical research company’s stock valued at $154,000 after acquiring an additional 251 shares in the last quarter. Huntington National Bank raised its holdings in Icon Plc by 5.0% in the 2nd quarter. Huntington National Bank now owns 1,630 shares of the medical research company’s stock valued at $159,000 after acquiring an additional 77 shares in the last quarter. Finally, Quantbot Technologies LP raised its holdings in Icon Plc by 40.9% in the 1st quarter. Quantbot Technologies LP now owns 2,022 shares of the medical research company’s stock valued at $161,000 after acquiring an additional 587 shares in the last quarter. 90.62% of the stock is owned by hedge funds and other institutional investors.
ICLR has been the subject of several analyst reports. ValuEngine cut Icon Plc from a “buy” rating to a “hold” rating in a report on Wednesday, May 31st. Credit Suisse Group reaffirmed an “outperform” rating and issued a $102.00 price objective (up from $91.00) on shares of Icon Plc in a report on Tuesday, June 6th. Robert W. Baird dropped their price objective on Icon Plc from $107.00 to $97.00 and set an “outperform” rating for the company in a report on Friday, June 9th. BidaskClub cut Icon Plc from a “strong-buy” rating to a “buy” rating in a report on Friday, June 16th. Finally, Zacks Investment Research raised Icon Plc from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a report on Tuesday, June 27th. Three research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. Icon Plc presently has an average rating of “Buy” and a consensus target price of $113.67.
Icon Plc (NASDAQ ICLR) opened at 111.34 on Friday. The stock has a 50 day moving average price of $108.18 and a 200 day moving average price of $93.43. The company has a market cap of $6.02 billion, a price-to-earnings ratio of 22.58 and a beta of 0.61. Icon Plc has a 52 week low of $73.76 and a 52 week high of $117.53.
Icon Plc (NASDAQ:ICLR) last issued its quarterly earnings data on Thursday, July 27th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.30 by $0.01. Icon Plc had a return on equity of 28.72% and a net margin of 15.97%. The company had revenue of $431.00 million for the quarter, compared to the consensus estimate of $430.68 million. During the same quarter last year, the business posted $1.14 earnings per share. The firm’s revenue was up 5.0% compared to the same quarter last year. On average, equities analysts forecast that Icon Plc will post $5.32 earnings per share for the current year.
Icon Plc Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.